• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Abbott, J&J spotlight clinical successes in coronary intravascular lithotripsy

November 2, 2026 By Conor Hale

Shockwave Medical Johnson & Johnson MedTech Javelin peripheral IVL catheter (1)
The Javelin IVL catheter. [Image courtesy of Johnson & Johnson MedTech]
Abbott and Johnson & Johnson both put forward separate clinical studies for their platforms for coronary intravascular lithotripsy, or IVL, designed to break through hardened plaque in the arteries feeding the heart muscle.

Both trials demonstrated low rates of complications after 30 days, and were largely able to cross through lesions for a successful procedure. They were presented at the Transcatheter Cardiovascular Therapeutics (TCT 2026) conference being held in San Diego.

Abbott (NYSE: ABT) said its SonicForce system met its primary endpoints in a pivotal trial of about 330 patients with severely calcified and previously untreated coronary artery disease. Its balloon catheter delivers acoustic pressure waves to crack through calcium deposits before the placement of a stent, helping it to fully expand.

After one month, the company’s TECTONIC study reported a treated lesion failure rate of 0.3%, after recording a procedural success rate of 97%. Following treatment and delivery of a drug-eluting stent, 98.5% of cases were able to reach residual stenosis levels of 30% or lower, confirmed by angiography.

A sub-study of patients who also underwent optical coherence tomography imaging logged 50 out of 80 lesions demonstrating signs of calcium fracture after IVL, along with 53 out of 80 after stenting, allowing for more favorable stent expansion.

“The investigational SonicForce System has the potential to expand Abbott’s broad range of access-to-closure devices, strengthen our leadership in treating severely calcified coronary arteries, and reinforce our commitment to equip physicians with integrated solutions for patients at every stage of care,” Julie Tyler, senior VP of Abbott’s vascular business, said in a statement.

TECTONIC’s results were also published in JACC: Cardiovascular Interventions. The study plans to follow participants through two years.

Related: J&J launches faster Shockwave coronary catheter in the US

Johnson & Johnson MedTech had positive results for IVL, too

Meanwhile, J&J (NYSE: JNJ) spotlighted data from its Shockwave Javelin catheter, designed to project forceful energy ahead of its tip with a single emitter instead of around its circumference to help clear a way through difficult lesions.

Its single-arm FORWARD CAD study met its endpoints examining 158 patients, reporting a 93.6% technical success rate and 93.4% freedom from major cardiovascular complications, including death, heart attack or the need for a repeat procedure after 30 days.

According to the company, 96% of cases were moderately or severely calcified, with an average reduction in inner vessel diameters of 81%. Chronic total blockages were found in 20% of lesions.

“Successfully treating heavily calcified lesions begins with being able to facilitate lesion crossing, an enduring challenge that can limit what physicians can achieve for patients,” said the study’s co-principal investigator, Dr. Robert Yeh, interventional cardiology section chief at Beth Israel Deaconess Medical Center.

“These findings represent an important step toward overcoming that barrier and creating a viable treatment path for patients whose disease may be beyond the reach of conventional balloon-based calcium modification approaches,” Yeh said.

The Javelin system was  previously launched in the U.S. in early 2025 for use in peripheral arteries. Earlier this month, J&J began rolling out the latest version of its circumferential coronary catheter, the Shockwave C2 Aero Fly, which delivers ultrasonic energy twice as fast as its previous version.

While J&J’s Shockwave division has had an early lead in the space, following its $13.1 billion acquisition in 2024, Boston Scientific and Stryker are also targeting the sector.

Earlier this year, Boston Scientific’s Seismiq coronary IVL system met its endpoints in a pivotal trial — while Stryker reported enrolling its first participants for a study of its Pulse system, acquired through its $835 million buy of Amplitude Vascular Systems, finalized in May.

Filed Under: Applications, Balloons, Cardiology, Catheters, Research, Research & Development, Technologies & Devices Tagged With: Abbott, intravascular lithotripsy, Johnson & Johnson, johnson & johnson medtech, TCT 2026

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | RSS